Why carry out this study?

Intraocular inflammation (IOI)-related adverse events (AEs) have been associated with the use of brolucizumab, but current real-world data are from studies with either small sample sizes or with a relatively short follow-up period.

What was learned from the study?

In the 482 patients who received ≥ 1 injection with brolucizumab between 1 October 2019 and 30 November 2021 at one of the Retina Associates of Cleveland Inc, clinics in Northeast Ohio, USA, IOI-related AEs were identified in 22 (4.6%) eyes.

The risk of an IOI-related AE decreased with time since first brolucizumab injection and number of previous brolucizumab injections. Three of the 22 eyes (14%) eyes had ≥ 5-letter loss within 6 months of AE resolution (or stability for occlusions) compared with before the event.

With appropriate monitoring, particularly during the first months of therapy, and management of IOI-related AEs, vision loss associated with brolucizumab may be limited.